Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

502 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Magnetic resonance imaging captures the biology of ductal carcinoma in situ.
Esserman LJ, Kumar AS, Herrera AF, Leung J, Au A, Chen YY, Moore DH, Chen DF, Hellawell J, Wolverton D, Hwang ES, Hylton NM. Esserman LJ, et al. Among authors: moore dh. J Clin Oncol. 2006 Oct 1;24(28):4603-10. doi: 10.1200/JCO.2005.04.5518. J Clin Oncol. 2006. PMID: 17008702 Free PMC article.
Ductal carcinoma in situ in BRCA mutation carriers.
Hwang ES, McLennan JL, Moore DH, Crawford BB, Esserman LJ, Ziegler JL. Hwang ES, et al. Among authors: moore dh. J Clin Oncol. 2007 Feb 20;25(6):642-7. doi: 10.1200/JCO.2005.04.0345. Epub 2007 Jan 8. J Clin Oncol. 2007. PMID: 17210933
Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer.
Garwood ER, Kumar AS, Baehner FL, Moore DH, Au A, Hylton N, Flowers CI, Garber J, Lesnikoski BA, Hwang ES, Olopade O, Port ER, Campbell M, Esserman LJ. Garwood ER, et al. Among authors: moore dh. Breast Cancer Res Treat. 2010 Jan;119(1):137-44. doi: 10.1007/s10549-009-0507-x. Breast Cancer Res Treat. 2010. PMID: 19728082 Free PMC article. Clinical Trial.
Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome.
Campbell MJ, Tonlaar NY, Garwood ER, Huo D, Moore DH, Khramtsov AI, Au A, Baehner F, Chen Y, Malaka DO, Lin A, Adeyanju OO, Li S, Gong C, McGrath M, Olopade OI, Esserman LJ. Campbell MJ, et al. Among authors: moore dh. Breast Cancer Res Treat. 2011 Aug;128(3):703-711. doi: 10.1007/s10549-010-1154-y. Epub 2010 Sep 15. Breast Cancer Res Treat. 2011. PMID: 20842526 Free PMC article.
Biologic markers determine both the risk and the timing of recurrence in breast cancer.
Esserman LJ, Moore DH, Tsing PJ, Chu PW, Yau C, Ozanne E, Chung RE, Tandon VJ, Park JW, Baehner FL, Kreps S, Tutt AN, Gillett CE, Benz CC. Esserman LJ, et al. Among authors: moore dh. Breast Cancer Res Treat. 2011 Sep;129(2):607-16. doi: 10.1007/s10549-011-1564-5. Epub 2011 May 20. Breast Cancer Res Treat. 2011. PMID: 21597921 Free PMC article.
Elevated levels of proliferating and recently migrated tumor-associated macrophages confer increased aggressiveness and worse outcomes in breast cancer.
Mukhtar RA, Moore AP, Tandon VJ, Nseyo O, Twomey P, Adisa CA, Eleweke N, Au A, Baehner FL, Moore DH, McGrath MS, Olopade OI, Gray JW, Campbell MJ, Esserman LJ. Mukhtar RA, et al. Among authors: moore dh, moore ap. Ann Surg Oncol. 2012 Nov;19(12):3979-86. doi: 10.1245/s10434-012-2415-2. Epub 2012 May 24. Ann Surg Oncol. 2012. PMID: 22622474
502 results